This article has been corrected to make clear that Genomic Health expects to make IVD products available in France and Germany in 2020.

NEW YORK (GenomeWeb) – Following a year of major milestones, Genomic Health CEO Kim Popovits said that the company expects to sustain and grow its momentum in 2019 with a focus on increasing adoption of its core breast cancer product in the US, pushing international expansions, and continuing to diversify its test menu.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.